Sunitinib (Su) in Progressive Pancreatic Neuroendocrine Tumor (PNET) Administered in Different Treatment Lines

#1871

Introduction: Su has shown PFS improvement in patients (pt) with PNET in phase III trial

Aim(s): We evaluate metastatic PNET treated with Su after failure of previous treatment (tr) including Everolimus (Ev), to assess efficacy and safety also in late lines of tr, and to evaluate the sequence Su after Ev

Materials and methods: From February 2011 to November 2016, 21 PNET pt with progressive disease were treated with Su 37,5 mg orally daily in 5 Italian centers. Grading was G1, G2 and unknown in 4,15 and 2 pt. Previous tr included SSA, Ev, chemotherapy, PRRT; 1 pt received Su in I line, 4 pt in II line, 6 pt in III line, 6 pt in IV line, 3 pt in V line, 1 pt in VI line. Ev was previously administered in 15 pt. Pt were followed for evidence of toxicity, response using RECIST criteria, and survival

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marconcini R

Authors: Marconcini R, Bloise F, Pusceddu S, Femia D, Bongiovanni A,

Keywords: sunitinib,